Skip to main content
. Author manuscript; available in PMC: 2012 Mar 25.
Published in final edited form as: Eur J Pharmacol. 2011 Jan 22;655(1-3):52–58. doi: 10.1016/j.ejphar.2011.01.009

Figure 3. Effects of the GABAB receptor positive modulator BHF177 on ICSS performance during nicotine/saline withdrawal.

Figure 3

Data are expressed as the percentage of baseline thresholds obtained on the last day of pump exposure before removal of the minipump (mean ± SEM). The arrowhead indicates the time-point (30 h post-pump removal) when the GABAB receptor positive modulator BHF177 was administered. Asterisks (**P < 0.01, ***P < 0.001) indicate significantly elevated ICSS thresholds in nicotine-treated groups compared with the saline/0 mg/kg BHF177-treated group. Plus signs (+P < 0.05) indicate significant differences between each nicotine-treated group and its corresponding saline-treated group that received the same dose of BHF177 (Newman-Keuls post hoc test). The pound sign (#P < 0.05) indicates a significant main effect of BHF177.